Research ExplorerPublicationsCOVID-19 and stem cell transplantation; results from an EBMT...

COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey

Standard

COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. / Ljungman, Per; de la Camara, Rafael; Mikulska, Malgorzata; Tridello, Gloria; Aguado, Beatriz; Zahrani, Mohsen Al; Apperley, Jane; Berceanu, Ana; Bofarull, Rodrigo Martino; Calbacho, Maria; Ciceri, Fabio; Lopez-Corral, Lucia; Crippa, Claudia; Fox, Maria Laura; Grassi, Anna; Jimenez, Maria-Jose; Demir, Safiye Koçulu; Kwon, Mi; Llamas, Carlos Vallejo; Lorenzo, José Luis López; Mielke, Stephan; Orchard, Kim; Porras, Rocio Parody; Vallisa, Daniele; Xhaard, Alienor; Knelange, Nina Simone; Cedillo, Angel; Kröger, Nicolaus; Piñana, José Luis; Styczynski, Jan.

In: LEUKEMIA, Vol. 35, No. 10, 10.2021, p. 2885-2894.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ljungman, P, de la Camara, R, Mikulska, M, Tridello, G, Aguado, B, Zahrani, MA, Apperley, J, Berceanu, A, Bofarull, RM, Calbacho, M, Ciceri, F, Lopez-Corral, L, Crippa, C, Fox, ML, Grassi, A, Jimenez, M-J, Demir, SK, Kwon, M, Llamas, CV, Lorenzo, JLL, Mielke, S, Orchard, K, Porras, RP, Vallisa, D, Xhaard, A, Knelange, NS, Cedillo, A, Kröger, N, Piñana, JL & Styczynski, J 2021, 'COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey', LEUKEMIA, vol. 35, no. 10, pp. 2885-2894. https://doi.org/10.1038/s41375-021-01302-5

APA

Ljungman, P., de la Camara, R., Mikulska, M., Tridello, G., Aguado, B., Zahrani, M. A., Apperley, J., Berceanu, A., Bofarull, R. M., Calbacho, M., Ciceri, F., Lopez-Corral, L., Crippa, C., Fox, M. L., Grassi, A., Jimenez, M-J., Demir, S. K., Kwon, M., Llamas, C. V., ... Styczynski, J. (2021). COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. LEUKEMIA, 35(10), 2885-2894. https://doi.org/10.1038/s41375-021-01302-5

Vancouver

Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani MA et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. LEUKEMIA. 2021 Oct;35(10):2885-2894. https://doi.org/10.1038/s41375-021-01302-5

Bibtex

@article{80d3bb7045354a31a7cd8b92bed9b53a,
title = "COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey",
abstract = "This study reports on 382 COVID-19 patients having undergone allogeneic (n = 236) or autologous (n = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). The median age was 54.1 years (1.0-80.3) for allogeneic, and 60.6 years (7.7-81.6) for autologous HCT patients. The median time from HCT to COVID-19 was 15.8 months (0.2-292.7) in allogeneic and 24.6 months (-0.9 to 350.3) in autologous recipients. 83.5% developed lower respiratory tract disease and 22.5% were admitted to an ICU. Overall survival at 6 weeks from diagnosis was 77.9% and 72.1% in allogeneic and autologous recipients, respectively. Children had a survival of 93.4%. In multivariate analysis, older age (p = 0.02), need for ICU (p < 0.0001) and moderate/high immunodeficiency index (p = 0.04) increased the risk while better performance status (p = 0.001) decreased the risk for mortality. Other factors such as underlying diagnosis, time from HCT, GVHD, or ongoing immunosuppression did not significantly impact overall survival. We conclude that HCT patients are at high risk of developing LRTD, require admission to ICU, and have increased mortality in COVID-19.",
author = "Per Ljungman and {de la Camara}, Rafael and Malgorzata Mikulska and Gloria Tridello and Beatriz Aguado and Zahrani, {Mohsen Al} and Jane Apperley and Ana Berceanu and Bofarull, {Rodrigo Martino} and Maria Calbacho and Fabio Ciceri and Lucia Lopez-Corral and Claudia Crippa and Fox, {Maria Laura} and Anna Grassi and Maria-Jose Jimenez and Demir, {Safiye Ko{\c c}ulu} and Mi Kwon and Llamas, {Carlos Vallejo} and Lorenzo, {Jos{\'e} Luis L{\'o}pez} and Stephan Mielke and Kim Orchard and Porras, {Rocio Parody} and Daniele Vallisa and Alienor Xhaard and Knelange, {Nina Simone} and Angel Cedillo and Nicolaus Kr{\"o}ger and Pi{\~n}ana, {Jos{\'e} Luis} and Jan Styczynski",
note = "{\textcopyright} 2021. The Author(s).",
year = "2021",
month = oct,
doi = "10.1038/s41375-021-01302-5",
language = "English",
volume = "35",
pages = "2885--2894",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "10",

}

RIS

TY - JOUR

T1 - COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey

AU - Ljungman, Per

AU - de la Camara, Rafael

AU - Mikulska, Malgorzata

AU - Tridello, Gloria

AU - Aguado, Beatriz

AU - Zahrani, Mohsen Al

AU - Apperley, Jane

AU - Berceanu, Ana

AU - Bofarull, Rodrigo Martino

AU - Calbacho, Maria

AU - Ciceri, Fabio

AU - Lopez-Corral, Lucia

AU - Crippa, Claudia

AU - Fox, Maria Laura

AU - Grassi, Anna

AU - Jimenez, Maria-Jose

AU - Demir, Safiye Koçulu

AU - Kwon, Mi

AU - Llamas, Carlos Vallejo

AU - Lorenzo, José Luis López

AU - Mielke, Stephan

AU - Orchard, Kim

AU - Porras, Rocio Parody

AU - Vallisa, Daniele

AU - Xhaard, Alienor

AU - Knelange, Nina Simone

AU - Cedillo, Angel

AU - Kröger, Nicolaus

AU - Piñana, José Luis

AU - Styczynski, Jan

N1 - © 2021. The Author(s).

PY - 2021/10

Y1 - 2021/10

N2 - This study reports on 382 COVID-19 patients having undergone allogeneic (n = 236) or autologous (n = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). The median age was 54.1 years (1.0-80.3) for allogeneic, and 60.6 years (7.7-81.6) for autologous HCT patients. The median time from HCT to COVID-19 was 15.8 months (0.2-292.7) in allogeneic and 24.6 months (-0.9 to 350.3) in autologous recipients. 83.5% developed lower respiratory tract disease and 22.5% were admitted to an ICU. Overall survival at 6 weeks from diagnosis was 77.9% and 72.1% in allogeneic and autologous recipients, respectively. Children had a survival of 93.4%. In multivariate analysis, older age (p = 0.02), need for ICU (p < 0.0001) and moderate/high immunodeficiency index (p = 0.04) increased the risk while better performance status (p = 0.001) decreased the risk for mortality. Other factors such as underlying diagnosis, time from HCT, GVHD, or ongoing immunosuppression did not significantly impact overall survival. We conclude that HCT patients are at high risk of developing LRTD, require admission to ICU, and have increased mortality in COVID-19.

AB - This study reports on 382 COVID-19 patients having undergone allogeneic (n = 236) or autologous (n = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). The median age was 54.1 years (1.0-80.3) for allogeneic, and 60.6 years (7.7-81.6) for autologous HCT patients. The median time from HCT to COVID-19 was 15.8 months (0.2-292.7) in allogeneic and 24.6 months (-0.9 to 350.3) in autologous recipients. 83.5% developed lower respiratory tract disease and 22.5% were admitted to an ICU. Overall survival at 6 weeks from diagnosis was 77.9% and 72.1% in allogeneic and autologous recipients, respectively. Children had a survival of 93.4%. In multivariate analysis, older age (p = 0.02), need for ICU (p < 0.0001) and moderate/high immunodeficiency index (p = 0.04) increased the risk while better performance status (p = 0.001) decreased the risk for mortality. Other factors such as underlying diagnosis, time from HCT, GVHD, or ongoing immunosuppression did not significantly impact overall survival. We conclude that HCT patients are at high risk of developing LRTD, require admission to ICU, and have increased mortality in COVID-19.

U2 - 10.1038/s41375-021-01302-5

DO - 10.1038/s41375-021-01302-5

M3 - SCORING: Journal article

C2 - 34079042

VL - 35

SP - 2885

EP - 2894

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 10

ER -